1-7 of 7
Kenji Tamura
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid Tumors

Jun Sato, Toshio Shimizu, Takafumi Koyama, Satoru Iwasa, Akihiko Shimomura, Shunsuke Kondo, Shigehisa Kitano, Kan Yonemori, Yutaka Fujiwara, Kenji Tamura, Takuya Suzuki, Takao Takase, Reiko Nagai, Kohei Yamaguchi, Taro Semba, Zi-Ming Zhao, Min Ren, Noboru Yamamoto
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (9): 1783–1791.
https://doi.org/10.1158/1078-0432.CCR-21-3518
Published: 02 May 2022
View article titled, Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid Tumors
Open the PDF for Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

First-in-Human Phase 1 Study of MORAb-202, an Antibody–Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α–Positive Advanced Solid Tumors

Toshio Shimizu, Yutaka Fujiwara, Kan Yonemori, Takafumi Koyama, Jun Sato, Kenji Tamura, Akihiko Shimomura, Hiroki Ikezawa, Maiko Nomoto, Keiji Furuuchi, Ryo Nakajima, Takuma Miura, Noboru Yamamoto
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (14): 3905–3915.
https://doi.org/10.1158/1078-0432.CCR-20-4740
Published: 15 July 2021
View article titled, First-in-Human Phase 1 Study of MORAb-202, an Antibody–Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α–Positive Advanced Solid Tumors
Open the PDF for First-in-Human Phase 1 Study of MORAb-202, an Antibody–Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α–Positive Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Visualization of Intratumor Pharmacokinetics of [fam-] Trastuzumab Deruxtecan (DS-8201a) in HER2 Heterogeneous Model Using Phosphor-integrated Dots Imaging Analysis

Mikiko Suzuki, Shigehiro Yagishita, Kiyoshi Sugihara, Yusuke Ogitani, Tadaaki Nishikawa, Mayu Ohuchi, Takashi Teishikata, Takahiro Jikoh, Yasushi Yatabe, Kan Yonemori, Kenji Tamura, Kosei Hasegawa, Akinobu Hamada
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (14): 3970–3979.
https://doi.org/10.1158/1078-0432.CCR-21-0397
Published: 15 July 2021
View article titled, Visualization of Intratumor Pharmacokinetics of [fam-] Trastuzumab Deruxtecan (DS-8201a) in HER2 Heterogeneous Model Using Phosphor-integrated Dots Imaging Analysis
Open the PDF for Visualization of Intratumor Pharmacokinetics of [fam-] Trastuzumab Deruxtecan (DS-8201a) in HER2 Heterogeneous Model Using Phosphor-integrated Dots Imaging Analysis in another window
Includes: Supplementary data
Journal Articles

Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer

Lillian M. Smyth, Kenji Tamura, Mafalda Oliveira, Eva M. Ciruelos, Ingrid A. Mayer, Marie-Paule Sablin, Laura Biganzoli, Helen J. Ambrose, Jack Ashton, Alan Barnicle, Des D. Cashell, Claire Corcoran, Elza C. de Bruin, Andrew Foxley, Joana Hauser, Justin P.O. Lindemann, Rhiannon Maudsley, Robert McEwen, Michele Moschetta, Martin Pass, Vicky Rowlands, Gaia Schiavon, Udai Banerji, Maurizio Scaltriti, Barry S. Taylor, Sarat Chandarlapaty, José Baselga, David M. Hyman
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (15): 3947–3957.
https://doi.org/10.1158/1078-0432.CCR-19-3953
Published: 03 August 2020
View article titled, Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with <em>AKT1</em><sup>E17K</sup>-Mutant, ER-Positive Metastatic Breast Cancer
Open the PDF for Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with <em>AKT1</em><sup>E17K</sup>-Mutant, ER-Positive Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Serum miRNA–based Prediction of Axillary Lymph Node Metastasis in Breast Cancer

Sho Shiino, Juntaro Matsuzaki, Akihiko Shimomura, Junpei Kawauchi, Satoko Takizawa, Hiromi Sakamoto, Yoshiaki Aoki, Masayuki Yoshida, Kenji Tamura, Ken Kato, Takayuki Kinoshita, Yuko Kitagawa, Takahiro Ochiya
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (6): 1817–1827.
https://doi.org/10.1158/1078-0432.CCR-18-1414
Published: 15 March 2019
View article titled, Serum miRNA–based Prediction of Axillary Lymph Node Metastasis in Breast Cancer
Open the PDF for Serum miRNA–based Prediction of Axillary Lymph Node Metastasis in Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Whole-Exome Sequencing of Muscle-Invasive Bladder Cancer Identifies Recurrent Mutations of UNC5C and Prognostic Importance of DNA Repair Gene Mutations on Survival

Kai Lee Yap, Kazuma Kiyotani, Kenji Tamura, Tatjana Antic, Miran Jang, Magdeline Montoya, Alexa Campanile, Poh Yin Yew, Cory Ganshert, Tomoaki Fujioka, Gary D. Steinberg, Peter H. O'Donnell, Yusuke Nakamura
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (24): 6605–6617.
https://doi.org/10.1158/1078-0432.CCR-14-0257
Published: 14 December 2014
View article titled, Whole-Exome Sequencing of Muscle-Invasive Bladder Cancer Identifies Recurrent Mutations of <em>UNC5C</em> and Prognostic Importance of DNA Repair Gene Mutations on Survival
Open the PDF for Whole-Exome Sequencing of Muscle-Invasive Bladder Cancer Identifies Recurrent Mutations of <em>UNC5C</em> and Prognostic Importance of DNA Repair Gene Mutations on Survival in another window
Includes: Supplementary data
Journal Articles

Expression of Novel Molecules, MICAL2-PV (MICAL2 Prostate Cancer Variants), Increases with High Gleason Score and Prostate Cancer Progression

Shingo Ashida, Mutsuo Furihata, Toyomasa Katagiri, Kenji Tamura, Yoshio Anazawa, Hiroki Yoshioka, Tsuneharu Miki, Tomoaki Fujioka, Taro Shuin, Yusuke Nakamura, Hidewaki Nakagawa
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (9): 2767–2773.
https://doi.org/10.1158/1078-0432.CCR-05-1995
Published: 04 May 2006
View article titled, Expression of Novel Molecules, MICAL2-PV (MICAL2 Prostate Cancer Variants), Increases with High Gleason Score and Prostate Cancer Progression
Open the PDF for Expression of Novel Molecules, MICAL2-PV (MICAL2 Prostate Cancer Variants), Increases with High Gleason Score and Prostate Cancer Progression in another window